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Objective: The aim of this study was to investigate the association between anti-hypertensive drugs, the risk of developing
an abdominal aortic aneurysm (AAA), aortic wall stiffness, collagen turnover, and change in aortic diameter.
Study Design, Setting and Methods: Data on present medication, smoking status, and medical history of participants in two
population-based aneurysm screening programs in the United Kingdom were collected by use of questionnaire. Aortic
elasticity was measured by M-mode ultrasound scanning. A serum radioimmunoassay of the amino-terminal propeptide
of type III procollagen was used to assess collagen turnover in one of the patient series.
Results: Data from 438 cases with an AAA >29 mm and 5373 controls were analyzed. Calcium-channel blockers were
independently associated with AAA. The odds ratio of having an AAA was 2.6 (95% confidence interval [CI], 1.5-4.2)
after adjusting for all relevant confounders. Other antihypertensive drugs showed no increased risk. No significant
differences in growth rates were found in cases exposed to any of the main antihypertensive drugs. An increased collagen
turnover was found in subjects receiving angiotensin-converting enzyme (ACE) inhibitors: 4.26 mg/L (95% CI,
3.73-4.79) compared with 3.62 mg/L (95% CI, 3.49-3.76) for subjects not receiving ACE inhibitors. No differences in
type III collagen turnover was found with use of any other antihypertensive drug. The mean aortic wall stiffness was
greater for all subjects exposed to calcium-channel blockers, whether with AAA or not: 25.1 arbitrary units (95% CI,
20.0-30.2) vs 19.3 (95% CI, 18.1-20.4)(P .002). By contrast, the mean stiffness for cases receiving ACE inhibitors was
smaller than for those not receiving ACE inhibitors: 19.0 (95% CI, 13.9-24.0) vs 25.2 (95% CI, 23.0-27.4).
Conclusions: Calcium-channel blockers were an independent risk factor for the presence of an AAA and were associated
with an increased arterial aortic wall stiffness. ACE inhibitors were associated with decreased stiffness and greater
collagen turnover. No significant effects on the growth rate of small aneurysms were detected. (J Vasc Surg 2002;36:
751-7.)
The structural integrity of the aortic wall depends to a
large extent on the extracellular matrix proteins elastin and
collagen.1-3 A large body of evidence suggests that aneu-
rysms are the result of a localized inflammatory process
resulting in complex remodeling that involves both the
synthesis and degradation of matrix proteins.4-12 Elastases
and collagenases belong to a family of structurally related
enzymes named matrix metalloproteinases (MMPs).
MMPs produced by inflammatory cells have been found in
human aneurysmal aortas and are seen as the main media-
tors of ground substance degradation.13-15 Various drugs
have been shown to reduce experimental aortic aneurysms
in animal models.16-18 Recent research showed that the
calcium-channel antagonist amlodipine potentiates elastase
and can increase growth of aneurysms in an animal mod-
el.19 Finally, some of the MMPs implicated in the metab-
olism of elastin or collagen, depend on zinc for their
activity.20-22 Captopril is a thiol that was specifically de-
signed to bind the zinc at the active site of angiotensin-
converting enzyme (ACE). Captopril and other ACE in-
hibitors may, therefore, influence the metabolism of matrix
proteins.22 This may have clinical implications, as it is well
known that patients with aneurysms are more likely to have
ischemic heart disease and hypertension than are individu-
als without aneurysms.23 The type of antihypertensive
treatment may have implications on the risk of developing
and the expansion rate of AAAs. The primary outcome
measures of this study were the association between anti-
hypertensive medication and risk of having an AAA, as
measured by the odds ratio. Secondary outcome measures
were differences in aortic expansion, aortic wall stiffness,
and collagen turnover between subjects exposed to antihy-
pertensive medication and those not exposed.
METHODS
The data used in this study were collected in two
prospective, longitudinal, population-based screening
studies in Chichester and Huntingdon, United King-
dom.24,25 Anteroposterior measurements of aortic diame-
ter were used in both centers. although in Chichester the
larger of the anteroposterior and transverse measurements
was used as the defining diameter.24 Methods of measure-
ment of the aortic diameter have been described previous-
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ly.26 A case was defined as a person with an infrarenal aortic
diameter of30 mm, and a control was defined as a person
with an infrarenal aortic diameter of30 mm. All cases and
controls from Chichester were included in this study. The
remainder of the subjects came from a screening program in
Huntingdon. The cohort of screened men in the Hunting-
don District over the age of 50 served as a basis for a nested
case-control study. All cases still attending the screening
program were selected for a case-control study and were
invited to participate. Controls were selected at random
from the screened population in Huntingdon with an aorta
of 25 mm wide on the first screen, to allow for a clear
distinction between cases and controls. Controls were
matched for age using frequency matching. We did not use
individual case-control matching.
Data about current smoking status, smoking history,
medical history, and drug history were obtained through a
self-administered questionnaire. The data from Hunting-
don came from a nested case-control study, whereas in
Chichester data were entered for all subjects who partici-
pated in the first screening round. Data about all prescribed
drugs were available for the Huntingdon patients, whereas
for the Chichester patients data for only cardiovascular
drugs were recorded in detail. We determined for every
patient the exposure to each of the major types of antihy-
pertensive drugs: beta blockers, calcium-channel blockers,
and ACE inhibitors. Smoking status was classified into
three categories: current smokers, ex-smokers, and non-
smokers. Subjects were classified as nonsmokers if they had
never smoked and as current-smokers if they were still
smoking. A positive history of ischemic heart disease was
recorded if the patient had sustained a myocardial infarc-
tion, had been admitted to a hospital for treatment of
angina, or had undergone a coronary bypass operation. In
both centers, blood pressure was measured automatically
with a Dinamap 1846 SXP (Critikon, Kettering, UK).
The growth data analyzed from both studies consisted
of age at first screen, and date and aortic diameter for all
follow-up scans. A summary of the follow-up data from
both centers has been published previously.27 The average
length of follow-up was 4 years (range, 6 months to 8
years). Each case was followed up with 6 monthly ultra-
sound scans. Growth was calculated by determining the
difference between first and last diameter and dividing this
difference by the length of follow-up in years.
Aortic elasticity was measured by M-mode ultrasound
scanning in the majority of subjects in Huntingdon by a
single ultrasonographer. We used a Toshiba Capasee with a
curvilinear 3.5 MHZ probe (Toshiba Medical Systems Ltd,
Crawley, UK).28 The elasticity was measured in the infra-
renal aorta at the same site that the diameter measurement
was obtained. The aortic diameter in systole and in diastole
was determined by freezing the M-mode picture if a clear
trace was obtained. In each patient, three measurements
were taken within 5 minutes of one other. The average of
three measurements was used for the stiffness calculations.
The elasticity of the aorta can be described as pressure strain
elastic modulus (Ep) or stiffness ().29 The stiffness index is
used here because it is less dependent on pulse pressure.30
For the Huntingdon patients, a blood sample was taken
for measurement of serum collagen turnover. Blood sam-
ples were taken at the time of the measurement of aortic
diameter and stiffness. The samples were centrifuged and
the serum frozen at20° C on the same day for analysis at
a later date. Batches of 80 serum samples were analyzed by
a single biochemist of the department of chemical pathol-
ogy at Hinchingbrooke hospital. The concentration of the
amino-terminal propeptide of type III procollagen (PII-
INP) was used as a proxy measurement of type III collagen
turnover, given that the aminoterminal propeptide is split
from the procollagen molecule during type III collagen
synthesis.31 The concentration of PIIINP was measured by
using an equilibrium type serum radioimmunoassay of the
amino-terminal propeptide of type III procollagen on the
basis of a highly purified specific human antigen (Pharmacia
& Upjohn Ltd, Diagnostics Division, Milton Keynes, UK).
We used duplicate 200-L aliquots of serum according to
the instructions of the manufacturer.32,33 The intraassay
and interassay coefficients of variation of this assay are less
than 5% and the sensitivity is 0.2 g/L. The reference
range for adults, based on data of Finnish blood donors was
1.7 to 4.2 g/L, with no differences between men and
women.32
Statistical analysis. Statistical analysis was performed
by using unconditional logistic regression methods to ad-
just for differences in age, gender, height, weight, place of
measurement, smoking status, blood pressure, history of
claudication, history of ischemic heart disease, and treat-
ment for hypertension.34 Hypotheses were tested by refer-
ring the log likelihood ratio to the 2 distribution, or using
the t test to compare mean values. We used STATA 5.0 for
Macintosh for all statistical analyses (Stata Corporation,
College Station, Texas).
RESULTS
Data for 5811 subjects were available for analysis: 2775
men and 3036 women. There were 438 cases with aortic
diameters larger than 29 mm and 5373 controls; 210 cases
came from Huntingdon and 228 from Chichester; 237
controls were from Huntingdon and 5136 controls came
from Chichester. In Huntingdon, only men were screened,
whereas men and women were screened in Chichester.
Ninety-one percent of cases were men and 9% women,
whereas 45% of the controls were men and 55% were
women. Data for cases and controls are shown in Table I.
The differences between cases and controls in height and
weight can be explained in part by differences in proportion
of men and women between cases and controls. The differ-
ences in diastolic blood pressure, however, were mainly
determined by place of measurement. Men in Huntingdon
had a significantly higher diastolic blood pressure than men
in Chichester: mean 84.8 mm Hg (95% confidence interval
[CI], 84.8-86.1 mm Hg) in Huntingdon compared to
79.4 mm Hg (95% CI, 78.9-79.9 mm Hg) in Chichester.
Systolic blood pressure did not differ markedly between the
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two places: 156.2 mm Hg (95% CI, 154.0-158.4 mm Hg)
in men from Huntingdon compared to 155.7 mm Hg (95%
CI, 154.6-156.8 mm Hg) in men from Chichester.
Crude and adjusted odds ratios, used to estimate the
association between antihypertensive drugs and AAA, are
shown in Table II. The association for all antihypertensive
drugs, except calcium-channel blockers, disappeared when
adjusted for age, gender, height, weight, place of measure-
ment, smoking status, blood pressure, history of ischemic
heart disease, history of claudication, and treatment for
hypertension.
Longitudinal data of 216 cases from Huntingdon and
129 cases from Chichester were analyzed to investigate
whether antihypertensive medication influences the expan-
sion of AAA. Growth data were used for analysis if the
measurements were at least 6 months apart. Table III
shows the mean growth rates per year for cases exposed to
certain antihypertensive drugs and nonexposed cases. No
significant differences were found in growth rate between
cases exposed to any of the main antihypertensive medica-
tions and those not exposed.
In 246 controls and 201 cases, a serum PIIINP mea-
surement was available to assess type III collagen turnover.
The mean collagen turnover in cases was 3.73 g/L (95%
CI, 3.53-3.93) compared to 3.65 g/L (95% CI, 3.49-
3.81). This difference is not statistically significant (P 
.52) and both mean values are in the normal range. There
were no statistically significant differences in type III colla-
gen turnover between subjects receiving calcium-channel
blockers, diuretics, or betablockers and subjects not ex-
posed to these drugs. However there was a marked increase
in mean collagen turnover between subjects receiving ACE
inhibitors compared to those not receiving ACE inhibitors
(Table IV).
Table I. Main characteristics of cases and controls
Men Women
Variable Cases Controls P Cases Controls P
Number 397 2414 41 2995
Age (y) 72 72 .78 74 72 .03
Current smoker 37% 9%  .001 0% 1% .051
Ex-smoker 53% 71%  .001 63% 45% .051
Nonsmoker 10% 21%  .001 37% 54% .051
On antihypertensive drugs 32% 21% .002 34% 25% .36
Mean systolic blood pressure (mm Hg) 158 155 .03 168 163 .26
Mean diastolic blood pressure(mm Hg) 85 80  .001 83 79 .05
History of ischemic heart disease 21% 10%  .001 15% 5% .009
History of claudication 19% 12%  .001 32% 12% .001
Mean height (cm) 173 172 .001 161 158 .01
Mean weight (kg) 80 75  .001 64 63 .65
Data are percentages unless otherwise indicated. Cases were defined as subjects with an aortic diameter 29 mm; 210 cases came from Huntingdon and 228
from Chichester; 237 controls were from Huntingdon and 5136 controls came from Chichester. In Huntingdon only men were screened, whereas in
Chichester men and women were screened.
Table II. Relative risk of having an AAA
Drug n Exposed controls Exposed cases Crude OR 95% CI Adjusted OR 95% CI
Ca channel blocker 5811 260 (5) 62 (14) 3.2 2.4-4.4 2.6 1.5-4.3
ACE inhibitors 5811 179 (3) 28 (6) 2 1.3-3.0 0.7 0.3-1.5
Beta blockers 5811 664 (12) 86 (20) 1.7 1.4-2.2 0.6 0.4-1.1
Diuretics 5811 474 (9) 66 (15) 1.8 1.4-2.4 0.9 0.6-1.6
Data are n (%). Adjusted odds ratios were calculated using a logistic regression model adjusting for age, sex, screening program, height, weight, diastolic blood
pressure, smoking status, history of ischemic heart disease, history of claudication, and drug treatment for hypertension.
Table III. Growth rates
Drug
Exposed Not exposed
Pn growth/year n growth/year
Calcium channel 48 0.5 (0-1.1) 284 0.8 (0.5-1.1) .52
ACE Inhibitors 24 0.02 (0.6-0.7) 308 0.8 (0.5-1.1) .18
Diuretics 54 0.8 (0.1-1.5) 278 0.7 (0.4-1.1) .88
Beta blocker 77 0.8 (0.3-1.4) 255 0.7 (0.4-1.1) .82
Growth rates in mm per year with 95% CI. P values calculated using the t test.
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Measurements of the stiffness () of the aortic wall
were made for 197 cases with an AAA and 253 controls.
The mean stiffness for cases was 24.3 arbitrary units (95%
CI, 22.3-26.3) compared to 16.3 (95% CI, 15.2-17.4) for
controls (P  .001). The mean stiffness for all subjects
exposed to calcium-channel antagonists was 25.1 (95% CI,
20.0-30.2) compared to 19.3 (95% CI, 18.1-20.4) for
subjects not exposed to calcium-channel antagonists (P 
.01). The mean stiffness for cases receiving calcium-channel
antagonists was increased: 28.4 (95% CI, 21.1-35.5) com-
pared to 23.9 (95% CI, 21.8-25.9) to cases not exposed to
calcium-channel antagonists. However, the difference in
mean stiffness between exposed and nonexposed cases did
not reach statistical significance because of smaller numbers
(P .11). The entire frequency distribution curve for cases
receiving calcium-channel antagonists is shifted to the
right, indicating increased stiffness (Fig 1) in all cases
exposed to calcium-channel blockers. We found decreased
stiffness in cases receiving ACE inhibitors: the mean stiff-
ness in cases receiving ACE inhibitors was 19.0 arbitrary
units (95% CI, 13.9-24.0) compared to 25.2 (95% CI,
23.0-27.4) for cases not receiving ACE inhibitors (P 
.06). The cumulative frequency distribution curve is shifted
to the left for cases receiving ACE inhibitors. (Fig 2). The
difference between all subjects exposed to ACE inhibitors
and those not exposed was not statistically significant (P 
.28) (Table V).
DISCUSSION
This study has shown that calcium-channel blockers are
an independent risk factor for AAA. Unlike the association
with other antihypertensive drugs, this association re-
mained highly significant after adjusting for age, gender,
height, weight, place of measurement, smoking status,
blood pressure, history of claudication, history of ischemic
heart disease, and treatment for hypertension. We found an
increased stiffness in subjects exposed to calcium-channel
blockers, a decreased stiffness in cases exposed to ACE
inhibitors, and an increased collagen turnover in subjects
exposed to ACE inhibitors.
It seems unlikely that these results are chance findings
because all were highly significant. Selection bias was min-
imized because cases and controls were selected from the
same population. A possible source of bias lies in the fact
that data were derived from two separate populations.
However, both screening programs were community-
based and both districts are predominantly rural and have
an elderly, fairly affluent, and almost exclusively white
population. A confounding factor is that in Huntingdon
only men were screened, whereas in Chichester men and
women were screened, and aneurysms are more prevalent
in men than in women. Confounders on the basis of gender
or differences in measurement methods between the two
centers were all taken into account when interpreting the
results. For instance, a large part of the differences in height
and weight between cases and controls can be explained by
gender differences. The differences in diastolic blood pres-
sure may have been caused by different measurement meth-
ods in both places. We adjusted for gender, place of mea-
surement, height, weight, and blood pressure in a logistic
regression model to correct for spurious differences caused
by these confounders.
Subjects with an aneurysm are more likely to have a
history of ischemic heart disease, peripheral vascular dis-
ease, or hypertension than are subjects without an aneu-
rysm.23 Cases are, therefore, more likely to be taking anti-
hypertensive medication than controls. We adjusted for
treatment of hypertension, history of ischemic heart dis-
ease, and history of claudication. The association between
calcium-channel blockers and AAA was independent of
those confounders. Research in a porcine aneurysm model
has shown that the calcium-channel antagonist amlodipine
enhances elastase.19 This could explain the strong indepen-
Table IV. Collagen turnover as measured by serum PIIINP concentration
Drug No. exposed
Mean PIIINP
(g/L) No. not exposed
Mean PIIINP
(g/L) P
Calcium channel 45 3.53 (3.25-3.82) 368 3.70 (3.56-3.84) .65
ACE Inhibitors 35 4.26 (3.73-4.79) 378 3.62 (3.49-3.76) .007
Diuretics 64 3.95 (3.61-4.30) 349 3.63 (3.49-3.77) .08
Beta blockers 77 3.80 (3.52-4.08) 336 3.65 (3.51-3.80) .25
95% Confidence intervals of the mean between subjects exposed to classes of antihypertensive drugs and those not exposed. P values were calculated by
applying the t test to the log transformation of the mean PIIINP.
Fig 1. Cumulative frequency distribution graph of stiffness in
cases exposed and not exposed to calcium-channel blockers. The
cumulative probability (or percentiles) is depicted on the Y axis,
and stiffness in arbitrary units on the X axis.
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dent association between the calcium-channel blockers and
risk of developing an AAA.
Elastolysis is considered to be the primary event in
aneurysm formation.35-41 It seems plausible that risk fac-
tors associated with the initial development of aneurysms
may be different from those associated with further expan-
sion. The association of calcium-channel blockers with risk
of small aneurysms and the increased stiffness seen in sub-
jects receiving calcium-channel blockers support the theory
that calcium-channel blockers are an initiating risk factor,
affecting the function of elastin. This would also explain the
similar levels of collagen turnover between subjects ex-
posed to calcium-channel blockers and nonexposed sub-
jects. Calcium-channel blockers may be an important risk
factor for the initial development of aneurysms. No differ-
ences in growth were observed. However, data about du-
ration of exposure to antihypertensive medication were not
available. Furthermore, the observation period may be too
short to see differences in growth in these small aneurysms.
This study lacks sufficient power to make firm statements
about the effect of antihypertensive medication on growth
of small aneurysms.
ACE inhibitors showed the opposite risk factor profile.
A marked increased collagen turnover was seen in subjects
receiving ACE inhibitors and a significantly decreased stiff-
ness in cases exposed to ACE inhibitors, but not for con-
trols. The increased stiffness just failed to reach signifi-
cance at the 5% level, so this could be a chance finding.
However, the numbers were very small and the increased
collagen turnover was highly significant. Furthermore,
both findings are in keeping with each other. There is a
biological explanation for the effect of ACE inhibitors on
aneurysms because ACE inhibitors were specifically de-
signed to bind zinc, which is an essential cofactor for
some of the MMPs implicated in the metabolism of
elastin or collagen.22 Zinc is a known inhibitor of elas-
tase, whether it also inhibits some of the tissue inhibitors
of MMPs is unknown.42 This may explain our finding
that ACE inhibitors increase collagen turnover and de-
crease stiffness in small aneurysms. We could not confirm
an effect on growth rate of small aneurysms because the
majority of our aneurysms are small and have no or very
limited expansion rates. The observation period is too
short to see differences in growth in small aneurysms.
The numbers of patients on ACE inhibitors were very
small, so this study lacks power to detect a significant
difference in growth between cases exposed to ACE
inhibitors and those who are not.
The clinical implications of this study for the man-
agement of patients with aneurysms who have hyperten-
sion or cardiac failure are uncertain. This study shows
that calcium-channel blockers are an independent risk
factor for the development of AAA. Effects on growth
were not seen, but larger studies may be required to
show such effects. It seems likely that the effect of
calcium-channel blockers on aneurysms is an initiating
effect, since they mainly affect elastin metabolism.
Therefore, we would suggest selection of a beta blocker
or a diuretic, and not a calcium-channel blocker, as the
first choice in treatment for patients with hypertension
and a strong family history of AAA. The effect of calci-
um-channel blockers on aneurysms, that require an op-
eration, is likely to be less pronounced, as collagen
degradation becomes more important in larger aneu-
rysms.43 Betablockers significantly reduce cardiac mor-
tality after major vascular surgery.44,45 It may, therefore,
be prudent to switch a patient, who needs an AAA repair,
from a calcium-channel blocker to a beta blocker if the
calcium-channel antagonist was prescribed for hyperten-
sion only and not for angina. Further studies are needed
to investigate the effect of ACE inhibitors on aneurysms
before any recommendations can be made.
Table V. Stiffness measurements of the arterial wall made by M-mode ultrasound according to exposure to
antihypertensive drugs.
Drug No. exposed Mean stiffness No. not exposed Mean stiffness P
Calcium channel 45 25.1 (20.0-30.2) 364 19.3 (18.1-20.4) .01
ACE inhibitors 31 18.1 (14.0-22.3) 378 20.0 (18.8-21.3) .28
Beta blockers 77 21.6 (18.6-24.6) 332 19.5 (18.2-20.8) .24
Diuretics 42 20.1 (16.6-23.6) 366 19.9 (18.6-21.1) .69
P values were calculated by applying the t test to the log transformation of the mean stiffness.
Fig 2. Cumulative frequency distribution graph of stiffness in
cases exposed and not exposed to ACE inhibitors. The cumulative
probability (or percentiles) is depicted on the Y axis and stiffness in
arbitrary units on the X axis.
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CONCLUSION
This study has shown that calcium-channel blockers are
an independent risk factor for abdominal aortic aneurysms.
Calcium channel blockers were associated with an increase
in the arterial wall stiffness. ACE inhibitors were associated
with an increase in type III collagen turnover. No signifi-
cant effect of antihypertensive drugs on growth of small
aneurysms was detected.
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